Schedule a Meeting
Download Brochure
Table of Content
Get a Price
March 2025
The genetic material market size is poised for significant growth from 2025 to 2034, driven by advancements in gene therapies, personalized medicine, and biopharmaceutical research. Increasing demand for genomic data, CRISPR-based gene editing, and synthetic biology applications is fueling market expansion. Key sectors, including healthcare, agriculture, and biotechnology, are investing in DNA and RNA-based technologies to enhance disease treatment, crop engineering, and bio-manufacturing. With rising government funding, regulatory support, and technological breakthroughs, the genetic material market is set to become a crucial component of the future bioeconomy.
A cell's genetic material is its inherited stuff. It contains all of the information unique to an organism. Both RNA (ribonucleic acid) and DNA (deoxyribonucleic acid) are named for them. The manipulation of live creatures' genetic material, or genetic engineering, has become a cutting-edge technique with profound effects on a range of sectors, including healthcare. Drug development in the pharmacy field has been transformed by genetic engineering, opening the door to novel therapies and customized medicine. The influence of genetic engineering on the pharmaceutical sector is examined in this article, along with significant developments and future prospects.
In recent years, artificial intelligence (AI) has become more and more significant in genomics research. AI has greatly advanced our knowledge of genetic diseases, medication development, and customized medicine. It has also shown itself to be a potent tool for evaluating and interpreting vast amounts of genomic data. Researchers can find genetic variants and mutations that could be linked to disease by using artificial intelligence (AI) to evaluate enormous volumes of genomic data. Drug development can potentially benefit from the use of AI algorithms to forecast how genes and proteins will work.
Rising Demand for Gene and Cell Therapies
The field of cell and gene therapies (CGTs) is expanding quickly due to innovation, which is also changing the standards of care by healing chronic illnesses, improving patient lives, and lessening the strain on healthcare systems throughout the globe. Allogeneic cell treatments, which can be produced in large quantities and given to patients in a manner similar to that of current medication therapies, are being developed by companies. A new age of healthcare with higher therapeutic originality and unheard-of treatment results is ushered in by the level of innovation and impending healthcare revolution symbolized by the introduction of CGTs.
Complexity in Data Interpretation
Because genetic data is inherently complicated, interpreting it is a daunting problem in the worldwide genetic material business. To extract valuable insights from genetic data analysis, specific knowledge in fields like bioinformatics, statistics, and molecular biology is required. Deciphering the complex information stored in genetic material and drawing useful conclusions applicable to clinical practice and research require this knowledge. However, a major barrier to optimizing the usefulness of genetic material analysis is the complex nature of genetic data interpretation, which calls for a sophisticated knowledge and skill set that may not always be accessible.
Research Collaboration & Technological Advancements
The main forces behind the developments in genetic material analysis are technological breakthroughs and cooperative research projects, which are creating enormous prospects for market growth. The capabilities of genetic material analysis have been transformed by advances in sequencing technology, gene editing tools, and data analytics platforms, which have allowed scientists and medical professionals to better understand biological systems and disease causes. These developments improve the accuracy, effectiveness, and scalability of genetic material analysis, opening the door for new genomic discoveries and making it easier to explore intricate genetic landscapes.
By type, the DNA segment held the largest share of the genetic material market in 2024. Today's civilization employs recombinant DNA (rDNA) for a variety of purposes from biotechnology and research to the medications found in pharmacies. Utilizing technology to control DNA synthesis has shown promise in a number of applications, some of which are listed below. Numerous initiatives to provide sustainable and scalable techniques for the production of medicines have been prompted by the growing need for pharmaceutical plasmid DNA.
By type, the RNA segment is estimated to grow at the fastest rate in the genetic material market during the forecast period. The use of different RNAs to selectively act on hitherto "undruggable" proteins, transcripts, and genes is encouraged by the improving understanding of RNA activities and their critical involvement in illnesses. This might expand the therapeutic targets. While several RNA-based drugs are still being studied or are undergoing preclinical trials, a few of them have been authorized for clinical use. To encourage RNA intracellular trafficking and metabolic stability, a number of strategies have been investigated.
By application, the genomics segment was dominant in the genetic material market in 2024. Drug discovery now offers more options thanks to genomics, especially high-throughput sequencing and characterization of human genes that are expressed. Understanding every human gene and how it works may help establish new medication development methods and research strategies, as well as enable effective preventative measures. The use of genomic technologies, including gene sequencing, statistical genetics, and gene expression analysis, to medications that are under clinical development and commercialization is known as pharmacogenomics.
By application, the drug discovery segment is anticipated to achieve notable growth in the genetic material market during the studied period. A drug's chances of success in clinical trials are increased when human genetic evidence supports the therapeutic theory. Genetics of both common and rare diseases provide a large number of alleles with varying impact sizes that can be used as a stand-in for a drug's influence on a condition. A wealth of human genetic data supporting medication target selection has been made available by recent developments in large-scale population collections and whole genome sequencing techniques.
By end-user, the pharmaceuticals segment held the major share of the genetic material market and is estimated to achieve significant growth during the forecast period. In order to produce biopharmaceuticals—drugs made from living things—genetic engineering has become essential. By introducing particular genes into host species like bacteria or yeast, recombinant DNA technology enables researchers to create therapeutic proteins like growth hormones, insulin, and antibodies. In addition to improving medication production efficiency, this technique has broadened the treatment choices that are now accessible.
North America dominated the genetic material market in 2024, propelled by a thriving biotechnology industry, significant expenditures in research and development, and sophisticated healthcare infrastructure. With a focus on genetic research and personalized treatment, the area sees a lot of use of genetic materials in biotechnological applications, medicines, and diagnostic tests, which promotes innovation and market expansion.
With biotech playing a major role, the healthcare industry drove U.S. initial public offerings (IPOs) in 2024, generating $6.6 billion and 23% of all IPO proceeds. A strong comeback in biotech public market activity is shown by this revival, and it is anticipated that this momentum will continue throughout 2025. Regulations in the biotechnology industry are enforced by the FDA, EPA, and USDA. Making ensuring the industry complies with the guidelines established by these regulatory agencies is the main goal of these regulations. The Food and Drug Administration (FDA), the Environmental Protection Agency (EPA), and the Department of Agriculture (USDA) collaborate to enforce laws pertaining to the biotechnology sector.
In Canada, the pharmaceutical industry is among the most inventive. The economic contribution of the pharmaceutical industry is demonstrated by a number of indicators, including the amount of taxes the industry pays to the government, employment and job creation, R&D investment, and foreign commerce. Important awarding partners such as the Canadian Institutes for Health Research have helped the Government of Canada fund research initiatives across the country. More than $2.3 billion has been invested by the Canadian government in 41 initiatives related to the biomanufacturing, vaccine, and pharmaceuticals ecosystem, enhancing the country's capacity to respond to pandemics and the advancement of life sciences.
Asia Pacific is estimated to host the fastest-growing genetic material market during the forecast period, driven by growing knowledge of genetic illnesses, growing healthcare spending, and developing healthcare infrastructure. The need for genetic testing services is rising in nations like China, India, and Japan as a result of changing lifestyles, urbanization, and population increase. Along with expenditures in genetic research and biotechnology, government measures to increase healthcare accessibility are driving market expansion in the Asia Pacific region and present substantial potential prospects for stakeholders and suppliers of genetic material.
In 2024, Chinese policymakers continued to prioritize the life sciences sector. China's pharmaceutical industry has shifted from producing generic medications to creating novel treatments. The number of novel medications in the development pipeline nearly doubled from 2,251 in 2021 to over 4,390 by the beginning of 2024. This increase in R&D shows a government-supported dedication to supporting scientific innovation and high-tech solutions. China is already a major player in the global life sciences industry because of investments in biotechnology, cell treatments, and customized medicine.
In terms of pharmaceutical output by volume, the Indian pharmaceutical industry is currently placed third after growing into a vibrant sector throughout time. Approximately 10,500 manufacturing plants and 3,000 pharmaceutical companies comprise the domestic pharmaceutical industry. In Asia Pacific, India is third in terms of biotechnology travel destinations, and it is in the top 12 worldwide. The country holds three to five percent of the global market for biotechnology. India's bioeconomy is predicted to grow from its 2022 valuation of US$137 billion to US$300 billion by 2030.
Europe is expected to be significantly growing in the genetic material market during the forecast period. Europe is a major player in the worldwide market for genetic material because of its strong healthcare system and rich scientific legacy. Nations such as the UK, Germany, and France are at the forefront of pharmaceutical innovation, genetic research, and diagnostic skills. The use of genetic materials in clinical diagnostics, research, and medicinal development is fueled by government assistance as well as partnerships between academia and business. This phenomenon is observed throughout the continent.
Investment in the German pharmaceutical business is now booming. In recent years, the pharmaceutical behemoths Roche from Switzerland, Eli Lilly from the United States, and Sanofi from France have made billion-dollar investments in German facilities. Eli Lilly is investing 2.3 billion euros to construct a cutting-edge diabetic pharmaceutical production plant in Alzey, Rhineland-Palatinate. Up to 1,000 new employees will be created as a result. Another driving force for public financing of significant developments is the German labor market. In increasingly specialized high-tech manufacturing, having highly skilled professionals in the domains of chemistry, biotechnology, and pharmaceuticals is a significant locational advantage.
Among comparable nations, the UK continues to have the second-highest budgetary expenditure for health research and development as a proportion of GDP after the United States. At 11.5% in 2023, the UK still contributes significantly to worldwide medical sciences citations, trailing only the United States and China. With pharmaceutical exports of £25.6 billion, the UK continued to rank tenth among comparators in 2023.
Unlock Infinite Advantages: Subscribe to Annual Membership
In December 2023, with $213 million in venture capital, biotechnology firm Tome Biosciences came out of stealth on Tuesday to create a novel gene editing method. “Prime and base editing is great for making small DNA changes, and PGI allows us to insert any DNA sequence of any size into any programmed location.” Chief Scientific Officer John Finn, a founding member of the gene editing business Intellia Therapeutics, added that CRISPR is fantastic for breaking genes.
By Type
By Application
By End User
By Region
March 2025
March 2025
March 2025
March 2025